Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br Acknowledgments This study was supported
2019-08-17
Acknowledgments This study was supported by grants from the Spanish Ministry of Economy and CompetitivenessPI10/00387, PI12/01087, PI12/01703, IPT-2011-0817-010000, and RIC Red de Investigación Cardiovascular (RIC)RD12/0042/0055. RIC is an initiative of Instituto de Salud Carlos III (ISCIII), Spa
-
In humans the ER is encoded by
2019-08-17
In humans, the ERα is encoded by the gene ESR1, located on chromosome 6, locus 6q25.1 (Gosden, Middleton, & Rout, 1986). In addition to the full-length ERα isoform (66kDa), several shorter isoforms (36kDa, 46kDa) have been identified as a result of the presence of alternate start codons, or as prod
-
br Significance Ubl post translational modifications
2019-08-17
Significance Ubl post-translational modifications are potential targets for developing novel therapeutics for life-threatening diseases, such as c-Myc- and KRas-driven cancers that lack targeted therapy. However, only a few drugs are available to target these modifications. This lack of drugs hig
-
There have been reports regarding the use of enolases
2019-08-17
There have been reports regarding the use of enolases as novel vaccine candidates for A. suum, S. suis, T. pisiformis and T. multiceps on account of this enzyme class\'s critical role in plasminogen activation and migration across tissue barriers (Chen et al., 2012; Zhang et al., 2009; Zhang et al.,
-
br Coactivator Binding Sets APC C Catalytic Core in Motion
2019-08-17
Coactivator Binding Sets APC/C Catalytic Core in Motion A coactivator not only recruits substrates to APC/C [18] (Figure 3B), but also stimulates repositioning of the catalytic core 19, 24. High-resolution cryo-EM maps of apo forms of APC/C without a coactivator show the catalytic core and platfo
-
In this study using REMD with the crystal environment we
2019-08-17
In this study, using REMD with the crystal environment, we investigate the effect of cryo-cooling on the crystal structure of Escherichia coli DHFR. DHFR is an important model enzyme (for review, see, e.g., (30)), and has been studied for decades (31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43).
-
The presence of external NAD P H dehydrogenases NDE
2019-08-17
The presence of external NAD(P)H dehydrogenases (NDE) on the outer surface of the inner mitochondrial membrane enables the mitochondria to oxidize cytosolic NAD(P)H (Moller 2001). A porin (a voltage-dependent anion-selective channel, VDAC) that is abundant in the outer mitochondrial membrane permits
-
br Results and discussion br Conclusion Novel and
2019-08-17
Results and discussion Conclusion Novel and selective aziridine-based inhibitors for the Leishmania mexicana protease LmCBP2.8 were discovered. Compounds 7d (Ki = 0.8 μM), 9d (Ki = 1.36 μM), 12d (Ki = 0.77 μM), 14d (Ki = 0.9 μM) and 18 (Ki = 0.441 μM) showed the highest potency and selectivity
-
br Acknowledgement br Introduction Recent developments
2019-08-17
Acknowledgement Introduction Recent developments in cancer immunotherapies have demonstrated durable responses, suggesting that effective immunotherapy would hold promise to improve patient outcome (Gunturu et al., 2013; Hodi et al., 2003; Lutz et al., 2011; Ribas et al., 2009). However, attem
-
We have previously characterized the leucine rich NESs
2019-08-17
We have previously characterized the leucine-rich NESs located within the zinc-binding domains of mucosal high risk HPV16 E7 (76IRTLEDLLM84) and low risk HPV11 E7 (76IRQLQDLLL84) mediating their nuclear export in a CRM1 dependent manner (Knapp et al., 2009, McKee et al., 2013). The zinc-binding doma
-
ICV injection of UCN or UCN performed in the morning
2019-08-17
ICV injection of UCN2 or UCN 3 performed in the morning of the 8th day (12h after the last IP administration) seems to increase further the time spent in the open arms of mice exposed to saline or nicotine treatment. Interestingly, in mice exposed to saline treatment ICV injection of UCN 2 or UCN 3
-
br COTSget based Architectures This
2019-08-16
COTSget-based Architectures This section describes how our COTSget-based architectures are defined. We use a design inspired by MDE to build a Domain-Specific Language (DSL) of the architecture, as can be seen in the metamodel of Fig. 3. This metamodel defines the abstract syntax of our DSL and i
-
Despite robust translation of GA
2019-08-16
Despite robust translation of GA, only small amounts of GR and GP were translated in cultured protease inhibitor cocktail and chick embryo spinal cord neural cells from the 75 copies of G4C2 in monocistronic constructs. Interestingly, GA is also the most common dipeptide found in autopsy tissue in F
-
Increased levels of PCNA monoubiquitination by
2019-08-16
Increased levels of PCNA monoubiquitination by UbL73P expression in a damage-independent manner mimics the phenotype observed for USP1 knockdown (Huang et al., 2006, Jones et al., 2012). USP1 is the only DUB to date shown to remove ubiquitin from PCNA in vivo. This finding reveals the highly dynamic
-
Current therapeutic interventions are directed
2019-08-16
Current therapeutic interventions are directed both to prevent (primarily by proper glycemic control) and to treat the advanced stages of diabetic retinopathy, when vision has already been significantly affected. Although these therapies can be very effective in preventing, delaying or reducing visi
15753 records 961/1051 page Previous Next First page 上5页 961962963964965 下5页 Last page